Moderna, Inc.
Moderna, Inc. (MRNA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MRNA · as of Jun 8, 2026
Key Statistics
Explore Moderna, Inc. Data
mrna stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 27 · Buy rate: 25.9%
The MRNA analyst consensus is Hold, based on ratings from 27 Wall Street analysts over the past 3 months. The average 12-month price target is $40.29, representing -15.07% downside from the current price of $47.44.
Competitors & Peers
mrna competitorsMRNA
BBIO
BMRN
CAI
EXEL
HALOStock Performance
Full HistoryAbout Moderna, Inc.
Moderna, Inc. a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardio…
what is moderna, inc. · mrna stock overview · moderna, inc. company profile · who is moderna, inc. ceo · mrna NASDAQ · moderna, inc. headquarters · moderna, inc. business segments
About Stock Overview & Key Data
Moderna, Inc. (MRNA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 7, 2018. As of the latest trading session, MRNA stock price is $47.44, with a market capitalization of $18.8B. The stock has returned +68.59% over the past 12 months and +60.87% year-to-date.
According to 27 Wall Street analysts, the consensus rating for Moderna, Inc. stock is Hold, with an average 12-month price target of $40.29. In fiscal year 2025, Moderna, Inc. reported revenue of $1.9B and net income of -$2.8B. For detailed data — including Moderna, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Moderna, Inc. (MRNA) stock price is $47.44. The stock is traded on NASDAQ under the ticker symbol MRNA. The 52-week range is $22.28 – $59.55.